candesartan cilexetil has been researched along with Hypertension, Renal in 10 studies
candesartan cilexetil: a prodrug which is metabolized to an active form candesartan to exert its biological effects
Hypertension, Renal: Persistent high BLOOD PRESSURE due to KIDNEY DISEASES, such as those involving the renal parenchyma, the renal vasculature, or tumors that secrete RENIN.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Candesartan was generally well tolerated; two patients withdrew for adverse events (fatigue and worsening glomerulopathy)." | 2.75 | Efficacy, safety and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age. ( Bagdasorova, IV; Drozdz, D; Gimpel, C; Hainer, JW; Montini, G; Schaefer, F; Sorof, J; Sugg, J; Teng, R; van de Walle, J; van Hoeck, K; Zurowska, A, 2010) |
| "Treatment with candesartan cilexetil caused significant decreases in blood pressure and amelioration of proteinuria and renal histological scores in the SHRSP/Izm rats." | 1.31 | Effects of AT1 receptor antagonist on proteoglycan gene expression in hypertensive rats. ( Nakaya, H; Saruta, T; Sasamura, H; Shimizu-Hirota, R, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (70.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schaefer, F | 1 |
| van de Walle, J | 1 |
| Zurowska, A | 1 |
| Gimpel, C | 1 |
| van Hoeck, K | 1 |
| Drozdz, D | 1 |
| Montini, G | 1 |
| Bagdasorova, IV | 1 |
| Sorof, J | 1 |
| Sugg, J | 1 |
| Teng, R | 1 |
| Hainer, JW | 1 |
| Nishiyama, A | 1 |
| Yoshizumi, M | 1 |
| Rahman, M | 1 |
| Kobori, H | 1 |
| Seth, DM | 1 |
| Miyatake, A | 1 |
| Zhang, GX | 1 |
| Yao, L | 1 |
| Hitomi, H | 1 |
| Shokoji, T | 1 |
| Kiyomoto, H | 1 |
| Kimura, S | 1 |
| Tamaki, T | 1 |
| Kohno, M | 1 |
| Abe, Y | 1 |
| Ito, K | 1 |
| Shiomi, M | 1 |
| Kito, G | 1 |
| Kim, S | 1 |
| Ohta, K | 1 |
| Hamaguchi, A | 1 |
| Omura, T | 1 |
| Yukimura, T | 1 |
| Miura, K | 1 |
| Inada, Y | 2 |
| Wada, T | 2 |
| Ishimura, Y | 1 |
| Chatani, F | 1 |
| Kanno, Y | 1 |
| Okada, H | 1 |
| Suzuki, H | 1 |
| Ikenaga, H | 1 |
| Saruta, T | 2 |
| Okamura, M | 1 |
| Konishi, Y | 1 |
| Nishimura, M | 1 |
| Umetani, N | 1 |
| Iwai, J | 1 |
| Negoro, N | 1 |
| Inoue, T | 1 |
| Takeda, T | 1 |
| Kanayama, Y | 1 |
| Nakamura, T | 1 |
| Obata, J | 1 |
| Onizuka, M | 1 |
| Kimura, H | 1 |
| Ohno, S | 1 |
| Yoshida, Y | 1 |
| Kawachi, H | 1 |
| Shimizu, F | 1 |
| Casellas, D | 1 |
| Benahmed, S | 1 |
| Artuso, A | 1 |
| Jover, B | 1 |
| Ojima, M | 1 |
| Sanada, T | 1 |
| Shibouta, Y | 1 |
| Nishikawa, K | 1 |
| Sasamura, H | 1 |
| Shimizu-Hirota, R | 1 |
| Nakaya, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Dose-ranging Safety and Pharmacokinetics Study of Candesartan Cilexetil in Hypertensive Pediatric Subjects 1 to Less That 6 Years of Age: A 4-week, Multicenter, Randomized, Double-blind Study With a 1-year, Open-label, Follow-up Period.[NCT00244621] | Phase 3 | 95 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00244621)
Timeframe: From randomisation to day 28
| Intervention | Percent change (Median) |
|---|---|
| Atacand .05 mg | -11.1 |
| Atacand .20 mg | -40.6 |
| Atacand .40 mg | -50.0 |
(NCT00244621)
Timeframe: From randomisation to day 28
| Intervention | Percent change (Median) |
|---|---|
| Atacand .05 mg | 0.0 |
| Atacand .20 mg | -29.2 |
| Atacand .40 mg | 0.0 |
(NCT00244621)
Timeframe: From randomisation to end of double-blind treatment (4 weeks)
| Intervention | mm Hg (Mean) |
|---|---|
| Atacand .05 mg | -5.2 |
| Atacand .20 mg | -7.9 |
| Atacand .40 mg | -11.1 |
(NCT00244621)
Timeframe: From randomisation to end of double-blind treatment (4 weeks)
| Intervention | mm Hg (Mean) |
|---|---|
| Atacand .05 mg | -6.0 |
| Atacand .20 mg | -8.9 |
| Atacand .40 mg | -12.0 |
1 trial available for candesartan cilexetil and Hypertension, Renal
| Article | Year |
|---|---|
Efficacy, safety and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2010 |
9 other studies available for candesartan cilexetil and Hypertension, Renal
| Article | Year |
|---|---|
Effects of AT1 receptor blockade on renal injury and mitogen-activated protein activity in Dahl salt-sensitive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl | 2004 |
Effects of the non-peptide angiotensin II receptor antagonist TCV-116 on systemic and renal hemodynamics in dogs with renal hypertension.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 1995 |
Renal protective effect of TCV-116 in stroke-prone spontaneously hypertensive rats.
Topics: Albuminuria; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Ben | 1994 |
Nonpeptide angiotensin II type 1 receptor antagonist prevents nephrosclerosis in hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Capto | 1994 |
Enhancement of hypertension and renal injury by salt-loading during chronic nitric oxide inhibition. Effects of TCV-116, a novel angiotensin II receptor antagonist.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Arginine; Benzimidazoles; Biphen | 1994 |
Candesartan prevents the progression of mesangioproliferative nephritis in rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressur | 1997 |
Candesartan and progression of preglomerular lesions in N(G)-nitro-L-arginine methyl ester hypertensive rats.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Bip | 1999 |
Comparison of the antihypertensive effects of the new angiotensin II (AT1) receptor antagonist candesartan cilexetil (TCV-116) and the angiotensin converting enzyme inhibitor enalapril in rats.
Topics: Administration, Oral; Angiotensin I; Angiotensin II; Angiotensin III; Angiotensin Receptor Antagonis | 1996 |
Effects of AT1 receptor antagonist on proteoglycan gene expression in hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biglycan; Biphen | 2001 |